Effect of acid suppression on the effectiveness of phosphate binders in haemodialysis patients”

Phase 4

Completed

• Conditions: Hyperphosphataemia; Kidney disease; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12610000437066
• Lead Sponsor: King Saud University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1- Currently receiving haemodialysis treatment for >1 month at The Queen Elizabeth Hospital, The Royal Adelaide Hospital, or affiliated satellite dialysis units (stable regimen during study period).
2- Patient receiving single agent phosphate binders (stable regimen during study period).
This include: Calcium Carbonate, Lanthanum Carbonate, Sevelamer hydrochloride, Aluminum Hydroxide.

Exclusion Criteria

1- < 18 years of age.
2- Patients unable to give informed consent.
3- Patients enrolled in other investigational drug treatments
4- Patients deemed unable to comply with treatment regime.
5- Home dialysis patients.
6- Peritoneal dialysis patients.
7- Severe indication for acid suppression where withdrawal of acid suppression therapy is deemed unacceptable by the caring physician. (e.g.)
a- Major active peptic ulcer diseases
b- Major recent gastrointestinal bleeding
C- Major Gastro-Oesophageal Reflux Disease (GORD)
d- Major gastro-intestinal problems on 7-point Global Overall Symptom (GOS28) scale.

Study & Design

• Study Type: Interventional
• Study Design: Not specified